BSJ-4-116 NEW
| Price | $50 | $113 | Get Latest Price |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-14 |
Product Details
| Product Name: BSJ-4-116 | CAS No.: 2519823-34-6 |
| Purity: 99.09% | Supply Ability: 10g |
| Release date: 2026/07/14 |
Product Introduction
Bioactivity
| Name | BSJ-4-116 |
| Description | BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM. It downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation). |
| In vitro | BSJ-4-116 (50?nM; 6-24?hours) decreases the level of CDK12 protein, regardless of the mutational status of the cell line.BSJ-4-116 (10-10000 nM; 72 hours) exhibits potent antiproliferative effects in Kelly CDK12C1039F.BSJ-4-116 inhibits the growth of T-ALL cells (Jurkat and MOLT-4 cells) and sensitizes them to PARP inhibition. BSJ-4-116 regulates DDR genes via poly(adenylation). BSJ-4-116 overcomes CDK12C1039F mutation. BSJ-4-116 represents the first example of resistance to a bivalent degrader molecule that is a consequence of an acquired point mutation in the target protein. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (298.55 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (5.97 mM), Sonication is recommended. |
| Keywords | PROTACs | mutation | Kelly | Inhibitor | inhibit | degrader | Cyclin dependent kinase | Cereblon | CDK12 | CDK | cancer | C1039F | BSJ-4-116 | BSJ4116 | BSJ 4 116 | antiproliferative |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Vepdegestrant | 2,4,6-Trihydroxybenzoic acid | Dinaciclib |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | High-Efficiency Gene Editing Small Molecule Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
| $46.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
|
VIP3Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2026-03-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY